Journal for Immunotherapy of Cancer

Article	Citations
TIGIT in cancer immunotherapy	377
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events	297
LAG-3: from molecular functions to clinical applications	257
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future	254
Tim-3 finds its place in the cancer immunotherapy landscape	230
Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity	214
Clinical landscape of oncolytic virus research in 2020	186
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinica	148
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometri	137
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events	131
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial	129
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial	127
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation	127
Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?	124
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice	124
ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma	123
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition	118
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy	117
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing	107
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation	106
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma	104
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies	103
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer	103
Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation	102
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer	102

Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma	101
Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes	99
Acute kidney injury in patients treated with immune checkpoint inhibitors	99
Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review	98
Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer	96
M1hottumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer	95
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer	94
Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers	92
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer	92
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead	92
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy	91
Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker	91
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer	90
IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma	89
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer	89
Therapeutic depletion of CCR8+tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy	89
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial	88
CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer	85
Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma	84
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study	83
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma	83
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial	83
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial	82
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma	81
Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy	80
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors	79
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial	79
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up	79
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC	78
Intratumoral TIGIT+ CD8+ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer	78
Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy	78
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma	78
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers	78
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations	77
Mitochondrial Lon-induced mtDNA leakage contributes to PD-L1–mediated immunoescape via STING-IFN signaling and extracellular vesicles	77
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1	76
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemothera	76
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone	76
Rethinking immune checkpoint blockade: ‘Beyond the T cell’	76
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study	75
Deregulation of HLA-I in cancer and its central importance for immunotherapy	75
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy	74
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors	74
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images	74
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial	74
Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer	73
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies	73
Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer	73
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma	72
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies	72

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma	71
T-cell agonists in cancer immunotherapy	70
Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery	70
Severity of COVID-19 in patients with lung cancer: evidence and challenges	70
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies	70
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade	69
TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer	69
Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity	69
Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study	68
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA	68
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy	67
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors	67
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade	67
Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10	67
Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy	66
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response	66
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer	66
Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity	66
Considerations for treatment duration in responders to immune checkpoint inhibitors	66
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors	65
Tumors establish resistance to immunotherapy by regulating Tregrecruitment via CCR4	65
Correction: Consensus guidelines for the definition, detection and interpretation of immunogenic cell death	65
CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy	65
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study	64
Antigen processing and presentation in cancer immunotherapy	64
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy	63
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)	63
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma	63
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages	63
Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance	62
Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade	62
Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival	62
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.	62
S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation	61
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors	61
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial	61
LRP1Bmutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types	60
Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis	59
Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck	59
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity	59
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy	59
Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy	59
Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy	59
Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma	59
Strategies for improving the management of immune-related adverse events	58
Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer	58
Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer	58
IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma	58
Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma	58
Evolving impact of long-term survival results on metastatic melanoma treatment	58
Lung metastases share common immune features regardless of primary tumor origin	58
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial	58
STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment	57
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma	57
Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer	57
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma	56
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)	56
CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer	56
Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma	56
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation	56
Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response	55
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer	55
Immunogenic ferroptosis and where to find it?	55
M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer	55
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma	55
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial	55
Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma	54
Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+conventional dendritic cells	53
Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas	53
A signature for pan-cancer prognosis based on neutrophil extracellular traps	52
Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy	52
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer	52
Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions	52
Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia	52
Chronic immune checkpoint inhibitor pneumonitis	52
CD200 promotes immunosuppression in the pancreatic tumor microenvironment	51
Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies	51
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL	51
Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study	51
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program	51

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study	50
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer	50
TFEB is a master regulator of tumor-associated macrophages in breast cancer	50
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy	50
C reactive protein impairs adaptive immunity in immune cells of patients with melanoma	49
Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3	49
Neutrophils in the era of immune checkpoint blockade	49
Aged neutrophils form mitochondria-dependent vital NETs to promote breast cancer lung metastasis	49
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma	49
Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities	49
Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity	49
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8	49
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study	48
Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines	48
Immunotherapy for sarcomas: new frontiers and unveiled opportunities	48
Lifting the innate immune barriers to antitumor immunity	48
Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma	48
Exercise and the immune system: taking steps to improve responses to cancer immunotherapy	48
Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function	48
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis	47
Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma	47
Role of Fcγ receptors in HER2-targeted breast cancer therapy	47
Point mutation inCD19facilitates immune escape of B cell lymphoma from CAR-T cell therapy	47
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19	47
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial	46
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort	46
STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer	46
Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response	46
GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma	45
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19	45
Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells	45
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer	45
Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer	45
Obesity diminishes response to PD-1-based immunotherapies in renal cancer	45
Cell death induced by cytotoxic CD8+T cells is immunogenic and primes caspase-3–dependent spread immunity against endogenous tumor antigens	45
Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma	44
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers	44
MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer	44
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)	44
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine	44
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from	44
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma	44
Overcoming hypoxia-induced functional suppression of NK cells	44
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemothe	44
CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype	44
Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis	44
Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study	43
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma	43
Interleukin-15 and cancer: some solved and many unsolved questions	43
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy	43
COVID-19 and immune checkpoint inhibitors: initial considerations	43
Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer	43
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL	43
Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer	43
Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes	43
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis	43
Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses	43
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung canc	42
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity	42
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy	42
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes	42
Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer	42
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study	42
Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherap	42
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes	42
Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors	42
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase	41
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies	41
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma	41
Role of immunotherapy in Ewing sarcoma	41
Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer	41
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition	41
Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma	41
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor	41
m6A modification patterns and tumor immune landscape in clear cell renal carcinoma	41
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor	40
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation	40
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors	40
Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration	40
CXCR6 deficiency impairs cancer vaccine efficacy and CD8+ resident memory T-cell recruitment in head and neck and lung tumors	40
Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis	40
Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma	40
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial	40
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy	40
ACE2andTMPRSS2expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19	39
Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma	39
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer	39
Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung	39
Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite	39
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma	39
CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity	39
Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial	38
Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity	38
CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer	38
Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis	38